Bringing data monitoring committee charters into the sunlight.

ClinicalTrials.gov Data monitoring committees charters

Journal

Clinical trials (London, England)
ISSN: 1740-7753
Titre abrégé: Clin Trials
Pays: England
ID NLM: 101197451

Informations de publication

Date de publication:
08 2023
Historique:
medline: 13 7 2023
pubmed: 26 5 2023
entrez: 26 5 2023
Statut: ppublish

Résumé

Clinical trials investigating novel or high risk interventions, or studying vulnerable participants, often use a data monitoring committee to oversee the progress of the trial. The data monitoring committee serves both an ethical and a scientific function, by protecting the interests of trial participants while ensuring the integrity of the trial results. A data monitoring committee charter, which typically describes the procedures by which data monitoring committees operate, contains details about the data monitoring committee's organizational structure, membership, meeting frequency, sequential monitoring guidelines, and the overall contents of data monitoring committee reports for interim review. These charters, however, are generally not reviewed by outside entities and are rarely publicly available. The result is that a key component of trial oversight remains in the dark. We recommend that ClinicalTrials.gov modify its system to allow uploading of data monitoring committee charters, as is already possible for other important study documents and that clinical trialists take advantage of this opportunity to voluntarily upload the data monitoring committee charter for trials that have one. The resulting cache of publicly available data monitoring committee charters should provide important insights for those interested in a particular trial, as well as for meta-researchers who wish to understand and potentially improve how this important component of trial oversight is actually being applied.

Identifiants

pubmed: 37231737
doi: 10.1177/17407745231169499
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

447-451

Commentaires et corrections

Type : CommentIn

Auteurs

David L DeMets (DL)

University of Wisconsin-Madison, Madison, WI, USA.

Deborah A Zarin (DA)

The MRCT Center of Brigham and Women's Hospital and Harvard, Cambridge, MA, USA.

Frank Rockhold (F)

Duke Clinical Research Institute/Duke University, Durham, NC, USA.

Susan S Ellenberg (SS)

University of Pennsylvania, Philadelphia, PA, USA.

Thomas Fleming (T)

University of Washington, Seattle, WA, USA.

Janet Wittes (J)

Wittes LLC, Washington, DC, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH